We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Spyre Therapeutics Inc (SYRE) USD0.0001

Sell:$29.76 Buy:$29.84 Change: $1.47 (4.68%)
Market closed |  Prices as at close on 18 July 2024 | Switch to live prices |
Change: $1.47 (4.68%)
Market closed |  Prices as at close on 18 July 2024 | Switch to live prices |
Change: $1.47 (4.68%)
Market closed |  Prices as at close on 18 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23).

Contact details

221 Crescent Street, Suite 105
United States
+1 (617) 6515940

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.57 billion
Shares in issue:
50.78 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Cameron Turtle
    Chief Executive Officer, Director
  • Scott Burrows
    Chief Financial Officer
  • Heidy King-Jones
    Chief Legal Officer, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.